Folgen
P Buchwald
P Buchwald
Director, Drug Discovery, Diabetes Research Institute, University of Miami, FL
Bestätigte E-Mail-Adresse bei med.miami.edu
Titel
Zitiert von
Zitiert von
Jahr
Soft drug design: general principles and recent applications
N Bodor, P Buchwald
Medicinal research reviews 20 (1), 58-101, 2000
3182000
Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems
N Bodor, P Buchwald
Advanced drug delivery reviews 36 (2-3), 229-254, 1999
2251999
Octanol-water partition: searching for predictive models
P Buchwald, N Bodor
Current medicinal chemistry 5 (5), 353-380, 1998
2201998
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, ...
Nature communications 6 (1), 7419, 2015
2012015
FEM-based oxygen consumption and cell viability models for avascular pancreatic islets
P Buchwald
Theoretical Biology and Medical Modelling 6, 1-13, 2009
1942009
FEM-based oxygen consumption and cell viability models for avascular pancreatic islets
P Buchwald
Theoretical Biology and Medical Modelling 6 (1), 5, 2009
1942009
Oscillatory dynamics of Cdc42 GTPase in the control of polarized growth
M Das, T Drake, DJ Wiley, P Buchwald, D Vavylonis, F Verde
Science 337 (6091), 239-243, 2012
1812012
Small‐molecule protein–protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations
P Buchwald
IUBMB life 62 (10), 724-731, 2010
1482010
A local glucose-and oxygen concentration-based insulin secretion model for pancreatic islets
P Buchwald
Theoretical biology and medical modelling 8, 1-25, 2011
1462011
Molecular size based approach to estimate partition properties for organic solutes
N Bodor, P Buchwald
The Journal of Physical Chemistry B 101 (17), 3404-3412, 1997
1361997
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems
N Bodor, P Buchwald
The AAPS journal 7, E820-E833, 2005
1142005
Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease
N Bodor, P Buchwald
Drug discovery today 7 (14), 766-774, 2002
1092002
Quantitative structure− metabolism relationships: Steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters
P Buchwald, N Bodor
Journal of medicinal chemistry 42 (25), 5160-5168, 1999
971999
Direct, differential‐equation‐based in‐vitro–in‐vivo correlation (IVIVC) method
P Buchwald
Journal of pharmacy and pharmacology 55 (4), 495-504, 2003
912003
Drug targeting via retrometabolic approaches
N Bodor, P Buchwald
Pharmacology & therapeutics 76 (1-3), 1-27, 1997
901997
Methylene blue inhibits the SARS-CoV-2 spike–ACE2 protein-protein interaction–a mechanism that can contribute to its antiviral activity against COVID-19
D Bojadzic, O Alcazar, P Buchwald
Frontiers in pharmacology 11, 600372, 2021
882021
Brain-targeted drug delivery: experiences to date
N Bodor, P Buchwald
American Journal of Drug Delivery 1, 13-26, 2003
882003
Small-molecule inhibitors of the coronavirus spike: ACE2 protein–protein interaction as blockers of viral attachment and entry for SARS-CoV-2
D Bojadzic, O Alcazar, J Chen, ST Chuang, JM Condor Capcha, ...
ACS infectious diseases 7 (6), 1519-1534, 2021
872021
A simple, predictive, structure‐based skin permeability model
P Buchwald, N Bodor
Journal of Pharmacy and Pharmacology 53 (8), 1087-1098, 2001
872001
The food colorant erythrosine is a promiscuous protein–protein interaction inhibitor
L Ganesan, E Margolles-Clark, Y Song, P Buchwald
Biochemical pharmacology 81 (6), 810-818, 2011
822011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20